New England Journal of Medicine· 2014Q1

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw, Richard Aplenc et al.

5,436citations
Q1SCImago
2014year

Short summary

Chimeric antigen receptor (CAR) T cells targeting CD19 (CTL019) achieved a 90% complete remission rate in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), including those who failed prior treatments like stem-cell transplantation.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine